COVID-19 Coagulopathy: Whom to Anticoagulate and How? What Agents to…

Rush University Medical Center

S. Jain

Role of Anticoagulants and Antiplatelet Agents for Patients With COV…

CHEST 2022 Coverage

V. Balasubramanian

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

How do I Recognize and Treat the VEXAS Syndrome?

Cleveland Clinic Rheumatology

P. Grayson

Pulmonary Embolism: Role of Catheter-Based Interventions

Baylor College of Medicine

P. Loyalka

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

Thrombophilia Screening: Best Practices and Who Should Be Tested

COR2ED The Heart of Medical Education

S. Middeldorp, J. Connors

Recent Updates on Blinatumomab in ALL: FDA Approval in 1L and Incorp…

Sarah Tasian

The ABCs of the CBC - Overview and Practical Insights on RBC Paramet…

The Blood Project

W. Aird

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Recent Advances in Classical Hematology

Indy Hematology Review

R. Brodsky

Updates in Thrombosis and Anticoagulation

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

D. Garcia

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

Diagnosis of ITP (Including Differential Diagnosis) and Disease Mana…

Drew Provan

Clots in the Visceral and Cerebral Veins: Evidence, Guidelines and T…

Marc Zumberg

Challenges in Antithrombotic Management: Top 3 Challenges in 2023 fo…

James Douketis

ALL in Adults: Overview and Recent Advances

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Cassaday

2024 Benign Hematology Updates

University of Colorado Division of Hematology

L. Chu

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …

Fred Hutchinson Cancer Center

R. Cassaday